RA CAPITAL MANAGEMENT, L.P.
SEC insider (Form 3/4/5 filer). CIK 0001346824. Director & 10% Owner at Wave Life Sciences, Inc. (WVE) and 9 other issuers. 289 reported Form 4/5 transactions since Sep 2024; latest on Oct 5, 2026. Located in BOSTON, MA.
Companies RA CAPITAL MANAGEMENT, L.P. has filed insider reports for
- Wave Life Sciences, Inc. (WVE): Director, 10% Owner
- Vor Biopharma Inc. (VOR): 10% Owner
- Sionna Therapeutics, Inc. (SION): Director, 10% Owner
- Tyra Biosciences, Inc. (TYRA): Director, 10% Owner
- Artiva Biotherapeutics, Inc. (ARTV): Director, 10% Owner
- Septerna, Inc. (SEPN): Director, 10% Owner
- Freenome, Inc. (FRNM): Director, 10% Owner
- Parabilis Medicines, Inc. (PBLS): Director, 10% Owner
- Inhibikase Therapeutics, Inc. (IKT): 10% Owner
- Climb Bio, Inc. (CLYM): Director, 10% Owner
RA CAPITAL MANAGEMENT, L.P.
CIK: 0001346824
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (31)
Wave Life Sciences, Inc.
Vor Biopharma Inc.
Sionna Therapeutics, Inc.
Tyra Biosciences, Inc.
Artiva Biotherapeutics, Inc.
Septerna, Inc.
Freenome, Inc.
Parabilis Medicines, Inc.
Inhibikase Therapeutics, Inc.
Climb Bio, Inc.
ARS Pharmaceuticals, Inc.
Solid Biosciences Inc.
Werewolf Therapeutics, Inc.
Acrivon Therapeutics, Inc.
PepGen Inc.
Hemab Therapeutics Holdings, Inc.
LENZ Therapeutics, Inc.
Janux Therapeutics, Inc.
Nkarta, Inc.
Bicara Therapeutics Inc.
Acumen Pharmaceuticals, Inc.
Prelude Therapeutics Inc
Adicet Bio, Inc.
Mineralys Therapeutics, Inc.
Evommune, Inc.
SpyGlass Pharma, Inc.
Cidara Therapeutics, Inc.
Fulcrum Therapeutics, Inc.
89bio, Inc.
Jade Biosciences, Inc.
4D Molecular Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (289 total)
- Oct 5, 2026WVE
Wave Life Sciences, Inc.
AwardIndirect10.7K shares- - Oct 2, 2026VOR
Vor Biopharma Inc.
ExerciseIndirect500 shares at avg. $12.80$6K - Sep 17, 2026SION
Sionna Therapeutics, Inc.
SaleIndirect3.4M shares at avg. $6.32$21.6M - Sep 17, 2026SION
Sionna Therapeutics, Inc.
SaleIndirect33.8K shares at avg. $7.46$252K - Sep 15, 2026TYRA
Tyra Biosciences, Inc.
PurchaseIndirectPre-Funded Warrants (Right to Buy)
9.1M shares at avg. $22.03- - Sep 10, 2026ARTV
Artiva Biotherapeutics, Inc.
AwardIndirectDirector Stock Option (Right to Buy)
16.3K shares- - Sep 8, 2026ARTV
Artiva Biotherapeutics, Inc.
AwardIndirectDirector Stock Option (Right to Buy)
13.8K shares- - Aug 24, 2026VOR
Vor Biopharma Inc.
ExerciseIndirect1.5K shares at avg. $3.74$6K - Aug 12, 2026SEPN
Septerna, Inc.
SaleIndirect746.5K shares at avg. $42.50$31.7M - Aug 12, 2026SEPN
Septerna, Inc.
SaleIndirect746.5K shares at avg. $42.50$31.7M
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 5, 2026 | WVE Wave Life Sciences, Inc. | Award | 10,700 | - | $0 | Indirect |
| Oct 2, 2026 | VOR Vor Biopharma Inc. | Exercise | 500 | $12.80 | $6,400 | Indirect |
| Sep 17, 2026 | SION Sionna Therapeutics, Inc. | Sale | 3,415,011 | $6.32 | $21,582,870 | Indirect |
| Sep 17, 2026 | SION Sionna Therapeutics, Inc. | Sale | 33,800 | $7.46 | $252,148 | Indirect |
| Sep 15, 2026 | TYRA Tyra Biosciences, Inc. | Purchase Pre-Funded Warrants (Right to Buy) | 9,078,529 | $22.03 | - | Indirect |
| Sep 10, 2026 | ARTV Artiva Biotherapeutics, Inc. | Award Director Stock Option (Right to Buy) | 16,250 | - | - | Indirect |
| Sep 8, 2026 | ARTV Artiva Biotherapeutics, Inc. | Award Director Stock Option (Right to Buy) | 13,750 | - | - | Indirect |
| Aug 24, 2026 | VOR Vor Biopharma Inc. | Exercise | 1,500 | $3.74 | $5,604 | Indirect |
| Aug 12, 2026 | SEPN Septerna, Inc. | Sale | 746,500 | $42.50 | $31,726,250 | Indirect |
| Aug 12, 2026 | SEPN Septerna, Inc. | Sale | 746,500 | $42.50 | $31,726,250 | Indirect |
1-10 of 289 transactions